Use of ceftaroline in the management of vertebral osteomyelitis case report

Infectious Diseases in Clinical Practice

Volumn 21, Issue 4, 2013, Pages 269-271

  Zainah, Hadeel ^a   Hammoud, Marwa ^a   Vazquez, Jose A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Ceftaroline; Osteomyelitis; Staphylococcus aureus

Indexed keywords

CEFTAROLINE; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL STRAIN; BONE BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISKITIS; DRUG SUBSTITUTION; DRUG USE; EPIDURAL ABSCESS; FASCIOCUTANEOUS FLAP; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; IMAGE GUIDED BIOPSY; LAMINECTOMY; LOW BACK PAIN; LUMBAR SPINE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOTOR DYSFUNCTION; NERVE ENDING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; SENSORY DYSFUNCTION; SPONDYLITIS; TREATMENT DURATION;

EID: 85027920692     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e318276959f     Document Type: Article

References (11)

1. Laudano JB. Ceftaroline fosamil: A new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(suppl 3):iii11-iii18.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious disease society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
3. Elyasi S, Khalili H, Dashti-Kavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68:1243-1255.
4. Wilcox MH, Corey RG, Talbot GH, et al. CANVAS 2: The second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv53-iv65.
5. Biek D, Critchley IA, Riccobene TA, et al. Ceftaroline fosamil: A novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother. 2010:65(suppl 4):iv9-iv16.
6. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: A randomized, double-blind, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):iii19-iii32.
7. Low DE, File TM Jr, Eckburg PB, et al. On behalf of the FOCUS 2 investigators. FOCUS 2: A randomized, double-blind, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):iii33-iii44.
8. Corey RG, Wilcox MH, Talbot GH, et al. CANVAS 1: The first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv41-iv51.
9. Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother. 2010;65(8):1749-1752.
10. Twilla JD, Gelfand MS, Cleveland KO, et al. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother. 2011;66(11):2675-2677.
11. Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep. 2012;4:4.